Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Clinical trial NCT04181060 · RECRUITING

Trial details

NCT number: NCT04181060
Sponsor: National Cancer Institute (NCI)
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Advanced Lung Non-Squamous Non-Small Cell Carcinoma Metastatic Lung Non-Squamous Non-Small Cell Carcinoma Recurrent Lung Non-Squamous Non-Small Cell Carcinoma Stage IIIB Lung Cancer AJCC v8 Stage IV Lung Cancer AJCC v8

Start date: 2020-12-28
Primary completion: 2026-12-31
Enrollment: 300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.